Pembrolizumab plus axitinib: a new treatment option for patients with metastatic renal cell carcinoma

被引：9
|
作者：
Mollica, Veronica [1 ]
Di Nunno, Vincenzo [1 ]
Massari, Francesco [1 ]
机构：
[1] St Orsola Marcello Malpighi Hosp, Div Oncol, Via Albertoni 15, I-40138 Bologna, Italy
来源：
CHINESE CLINICAL ONCOLOGY | 2019年 / 8卷
关键词：
D O I：
10.21037/cco.2019.04.05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma
    Miyake, Hideaki
    Harada, Ken-ichi
    Ozono, Seiichiro
    Fujisawa, Masato
    MEDICAL ONCOLOGY, 2016, 33 (08)
  • [42] Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study
    Huang, Jiwei
    Shi, Guohai
    Wang, Yueming
    Wang, Ping
    Zhang, Jin
    Kong, Wen
    Huang, Yiran
    Wang, Shuo
    Xue, Wei
    FUTURE ONCOLOGY, 2022, 18 (12) : 1461 - 1471
  • [43] Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
    Chau, Vincent
    Bilusic, Marijo
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 7321 - 7330
  • [44] Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy
    Yoshimura, Akihiro
    Yamamoto, Yoshiyuki
    Nishikawa, Tatsuya
    Fujita, Masashi
    Inoue, Takako
    Kondo, Fuki
    Hayashi, Takuji
    Kawamura, Norihiko
    Nagahara, Akira
    Nakai, Yasutomo
    Nakayama, Masashi
    Nishimura, Kazuo
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2024, 13 (01): : 26 - 32
  • [45] Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy
    Akihiro Yoshimura
    Yoshiyuki Yamamoto
    Tatsuya Nishikawa
    Masashi Fujita
    Takako Inoue
    Fuki Kondo
    Takuji Hayashi
    Norihiko Kawamura
    Akira Nagahara
    Yasutomo Nakai
    Masashi Nakayama
    Kazuo Nishimura
    International Cancer Conference Journal, 2024, 13 (1) : 26 - 32
  • [46] Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.
    Aran, Dvir
    Granot-Hershkovitz, Einat
    Amar-Farkash, Shlomit
    Rosenberg-Katz, Keren
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
    Kimura, Shoichi
    Fujisaki, Yukiya
    Onizuka, Chie
    Hasuike, Satoru
    Sato, Yuichiro
    Mukai, Shoichiro
    Kamoto, Toshiyuki
    IJU CASE REPORTS, 2023, 6 (04) : 206 - 210
  • [48] Axitinib in sequential therapy in metastatic renal cell carcinoma
    Kuchar, Agata
    Hryciuk, Beata
    Stec, Rafal
    Maczewski, Michal
    Szczylik, Cezary
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2016, 20 (05): : 418 - 420
  • [49] HEALTH STATE UTILITIES IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE PEMBROLIZUMAB PLUS AXITINIB OR SUNITINIB
    Bensimon, A.
    Lai, Y.
    Xu, R.
    Bhattacharya, R.
    Shinde, R.
    VALUE IN HEALTH, 2022, 25 (07) : S554 - S554
  • [50] Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordan
    Levin, Rebecca
    Vlahiotis, Anna
    Zanotti, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345